Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 7;12(3):413.
doi: 10.3390/biology12030413.

Whole-Exome Sequencing in Family Trios Reveals De Novo Mutations Associated with Type 1 Diabetes Mellitus

Affiliations

Whole-Exome Sequencing in Family Trios Reveals De Novo Mutations Associated with Type 1 Diabetes Mellitus

Mira Mousa et al. Biology (Basel). .

Abstract

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by insulin deficiency and loss of pancreatic islet β-cells. The objective of this study is to identify de novo mutations in 13 trios from singleton families that contribute to the genetic basis of T1DM through the application of whole-exome sequencing (WES). Of the 13 families sampled for this project, 12 had de novo variants, with Family 7 having the highest number (nine) of variants linked to T1DM/autoimmune pathways, whilst Family 4 did not have any variants past the filtering steps. There were 10 variants of 7 genes reportedly associated with T1DM (MST1; TDG; TYRO3; IFIHI; GLIS3; VEGFA; TYK2). There were 20 variants of 13 genes that were linked to endocrine, metabolic, or autoimmune diseases. Our findings demonstrate that trio-based WES is a powerful approach for identifying new candidate genes for the pathogenesis of T1D. Genotyping and functional annotation of the discovered de novo variants in a large cohort is recommended to ascertain their association with disease pathogenesis.

Keywords: T1D; WES; case–parent trios; de novo variants; diabetes; family trios; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Todd J.A. Etiology of type 1 diabetes. Immunity. 2010;32:457–467. doi: 10.1016/j.immuni.2010.04.001. - DOI - PubMed
    1. Atkinson M.A., Eisenbarth G.S., Michels A.W. Type 1 diabetes. Lancet. 2014;383:69–82. doi: 10.1016/S0140-6736(13)60591-7. - DOI - PMC - PubMed
    1. Katsarou A., Gudbjornsdottir S., Rawshani A., Dabelea D., Bonifacio E., Anderson B.J., Jacobsen L.M., Schatz D.A., Lernmark A. Type 1 diabetes mellitus. Nat. Rev. Dis. Prim. 2017;3:17016. doi: 10.1038/nrdp.2017.16. - DOI - PubMed
    1. Haller M.J., Atkinson M.A., Schatz D. Type 1 diabetes mellitus: Etiology, presentation, and management. Pediatric. Clin. 2005;52:1553–1578. doi: 10.1016/j.pcl.2005.07.006. - DOI - PubMed
    1. Craig M.E., Kim K.W., Isaacs S.R., Penno M.A., Hamilton-Williams E.E., Couper J.J., Rawlinson W.D. Early-life factors contributing to type 1 diabetes. Diabetologia. 2019;62:1823–1834. doi: 10.1007/s00125-019-4942-x. - DOI - PubMed